Proteasome regulation by reversible tyrosine phosphorylation at the membrane

Lu Chen,Yanan Zhang,Xin Shu,Qiong Chen,Tiantian Wei,Heman Wang,Xiaorong Wang,Qirou Wu,Xiaomei Zhang,Xiaoyan Liu,Suya Zheng,Lan Huang,Junyu Xiao,Chao Jiang,Bing Yang,Zhiping Wang,Xing Guo
DOI: https://doi.org/10.1038/s41388-021-01674-z
IF: 8.756
2021-02-18
Oncogene
Abstract:Reversible phosphorylation has emerged as an important mechanism for regulating 26S proteasome function in health and disease. Over 100 phospho-tyrosine sites of the human proteasome have been detected, and yet their function and regulation remain poorly understood. Here we show that the 19S subunit Rpt2 is phosphorylated at Tyr439, a strictly conserved residue within the C-terminal HbYX motif of Rpt2 that is essential for 26S proteasome assembly. Unexpectedly, we found that Y439 phosphorylation depends on Rpt2 membrane localization mediated by its N-myristoylation. Multiple receptors tyrosine kinases can trigger Rpt2–Y439 phosphorylation by activating Src, a N-myristoylated tyrosine kinase. Src directly phosphorylates Rpt2–Y439 in vitro and negatively regulates 26S proteasome activity at cellular membranes, which can be reversed by the membrane-associated isoform of protein tyrosine phosphatase nonreceptor type 2 (PTPN2). In H1975 lung cancer cells with activated Src, blocking Rpt2–Y439 phosphorylation by the Y439F mutation conferred partial resistance to the Src inhibitor saracatinib both in vitro and in a mouse xenograft tumor model, and caused significant changes of cellular responses to saracatinib at the proteome level. Our study has defined a novel mechanism involved in the spatial regulation of proteasome function and provided new insights into tyrosine kinase inhibitor-based anticancer therapies.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?